

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019**SECTION 1. IDENTIFICATION**

Product name : ENSPRYNG(TM) SC (120 mg/ml)
Product code : RO533-3787/F01
Common name(s), syno- : Satralizumab 12.0% aqueous solution with excipients
nym(s) of the substance

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.
Address : DNA Way 1
94080 South San Francisco
CA
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone :
Emergency telephone num- : US Chemtrec phone (800)-424-9300
ber

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Satralizumab	1535963-91-7	12.0
L-Arginine	74-79-3	2.6
L-Histidine	71-00-1	0.3
Poloxamer 188	691397-13-4	0.05
L-Aspartic acid	56-84-8	
Water	7732-18-5	> 85.0

ENSPRYNG(TM) SC (120 mg/ml)

Version
1.1

Revision Date:
08-18-2020

Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protection : Refer to protective measures listed in sections 7 and 8.

ENSPRYNG(TM) SC (120 mg/ml)

Version 1.1 Revision Date: 08-18-2020 Date of last issue: 04-18-2019
 Date of first issue: 04-18-2019

tive equipment and emergency procedures

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
 Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.
 Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Satralizumab	1535963-91-7	IOEL	10 µg/m3	

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

Material : Protective gloves

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Clear liquid, sterile

Color : colorless, light yellow

Odor : No data available

Odor Threshold : No data available

pH : 5.5 - 6.5

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : does not flash

Evaporation rate : No data available

Flammability (solid, gas) : Does not sustain combustion.

Flammability (liquids) : Does not sustain combustion.

Self-ignition : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Solubility(ies)
Water solubility : completely soluble

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

ENSPRYNG(TM) SC (120 mg/ml)

Version 1.1	Revision Date: 08-18-2020	Date of last issue: 04-18-2019 Date of first issue: 04-18-2019
----------------	------------------------------	---

Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	No data available
Oxidizing properties	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	Exposure to light. Heat.
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

SECTION 11. TOXICOLOGICAL INFORMATION
Acute toxicity

Not classified based on available information.

Components:
Satralizumab:

Acute oral toxicity	:	Remarks: Not bioavailable by oral administration
Acute toxicity (other routes of administration)	:	NOAEL (No observed adverse effect level) (cynomolgus monkey): 200 mg/kg Application Route: i.v. NOAEL (No observed adverse effect level) (cynomolgus monkey): 50 mg/kg

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

Application Route: s.c.

L-Arginine:

Acute oral toxicity : LD50 Oral (Rat): > 5,110 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**L-Arginine:**

Remarks : May cause skin irritation in susceptible persons.

Serious eye damage/eye irritation

Not classified based on available information.

Components:**L-Arginine:**Result : Irritating to eyes.
Remarks : May cause irreversible eye damage.**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.**Reproductive toxicity**

Not classified based on available information.

STOT-single exposure

Not classified based on available information.

Components:**L-Arginine:**

Assessment : The substance or mixture is not classified as specific target

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

organ toxicant, single exposure.

STOT-repeated exposure

Not classified based on available information.

Components:**L-Arginine:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity**Components:****Satralizumab:**Species : cynomolgus monkey
NOAEL : 50 mg/kg/w
Application Route : s.c.
Exposure time : 4 w
Remarks : Subacute toxicitySpecies : cynomolgus monkey
NOAEL : 50 mg/kg/w
Application Route : s.c.
Exposure time : 26 w
Remarks : Subchronic toxicity**Aspiration toxicity**

Not classified based on available information.

Components:**L-Arginine:**

No data available

Further information**Components:****Satralizumab:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Satralizumab:**

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 100 mg/l

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

aquatic invertebrates

Exposure time: 48 h
Test Type: Immobilization
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentrationNOEC (Daphnia magna (Water flea)): 100 mg/l
Exposure time: 48 h
Test Type: Immobilization
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentrationToxicity to algae/aquatic
plants: ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentrationEyC50 (Desmodesmus subspicatus (green algae)): > 100
mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentrationNOEC (Desmodesmus subspicatus (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration**L-Arginine:**

Toxicity to fish

: LC50 (Brachydanio rerio (zebrafish)): 2,800 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yesNOEC (Brachydanio rerio (zebrafish)): 1,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yesToxicity to daphnia and other
aquatic invertebrates: NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202
GLP: yes

Toxicity to microorganisms

: EC10 (Pseudomonas putida): < 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8
GLP: yes

ENSPRYNG(TM) SC (120 mg/ml)

Version
1.1

Revision Date:
08-18-2020

Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

Ecotoxicology Assessment

- Acute aquatic toxicity : This product has no known ecotoxicological effects.
- Chronic aquatic toxicity : This product has no known ecotoxicological effects.
- Toxicity Data on Soil : Not expected to adsorb on soil.
- Other organisms relevant to the environment : No data available

Persistence and degradability

Components:

Satralizumab:

- Biodegradability : Theoretical oxygen demand
Result: Readily biodegradable.
Biodegradation: 78 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

Bioaccumulative potential

Components:

Satralizumab:

- Partition coefficient: n-octanol/water : Remarks: No data available

L-Arginine:

- Partition coefficient: n-octanol/water : log Pow: -4.2

Mobility in soil

No data available

Other adverse effects

Product:

- Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

L-Arginine:

- Adsorbed organic bound halogens (AOX) : Remarks: Not applicable

ENSPRYNG(TM) SC (120 mg/ml)

Version 1.1 Revision Date: 08-18-2020 Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

SARA 311/312 Hazards : No SARA Hazards

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

ENSPRYNG(TM) SC (120 mg/ml)

Version
1.1

Revision Date:
08-18-2020

Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

US State Regulations

Massachusetts Right To Know

Pennsylvania Right To Know

Water	7732-18-5
Satralizumab	1535963-91-7

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

The ingredients of this product are reported in the following inventories:

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Satralizumab

Poloxamer 188

AICS : Not in compliance with the inventory

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory


TCSI : Not in compliance with the inventory

TSCA : Substance(s) not listed on TSCA inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

ENSPRYNG(TM) SC (120 mg/ml)Version
1.1Revision Date:
08-18-2020Date of last issue: 04-18-2019
Date of first issue: 04-18-2019**SECTION 16. OTHER INFORMATION****NFPA:****HMIS® IV:**

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances

SAFETY DATA SHEET

ENSPRYNG(TM) SC (120 mg/ml)

Version
1.1

Revision Date:
08-18-2020

Date of last issue: 04-18-2019
Date of first issue: 04-18-2019

Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 08-18-2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810